Welcome to our dedicated page for Kyverna Therapeutics news (Ticker: KYTX), a resource for investors and traders seeking the latest updates and insights on Kyverna Therapeutics stock.
Kyverna Therapeutics, Inc. (Nasdaq: KYTX) is a clinical-stage biopharmaceutical company focused on developing CD19-targeting CAR T-cell therapies for autoimmune diseases, and its news flow reflects this focus. Company updates frequently highlight progress with its lead autologous CAR T-cell therapy candidate, mivocabtagene autoleucel (miv-cel, KYV-101), in B-cell-driven autoimmune conditions.
Visitors to this KYTX news page can review announcements on Kyverna’s registrational trials in stiff person syndrome (SPS) and generalized myasthenia gravis (gMG). Recent press releases describe positive topline data from the KYSA-8 registrational Phase 2 trial in SPS and interim Phase 2 data from the KYSA-6 registrational Phase 2/3 trial in gMG, including reported effects on disability, mobility, and disease activity scores, as well as safety outcomes such as the absence of high-grade cytokine release syndrome or ICANS in the reported datasets.
News items also cover Kyverna’s broader development and financing activities. These include business updates and quarterly financial results, a loan facility with Oxford Finance LLC, and public equity offerings under an effective shelf registration statement on Form S-3. Additional releases describe investigator-initiated trials in multiple sclerosis and rheumatoid arthritis, Phase 1/2 trials in lupus nephritis, and the advancement of KYV-102, which the company characterizes as using a whole blood rapid manufacturing process.
Investors and followers of KYTX can use this page to track Kyverna’s press releases on clinical milestones, regulatory plans such as an anticipated BLA submission for SPS, corporate presentations at healthcare conferences, leadership and governance changes, and capital-raising transactions. Checking this feed provides a consolidated view of how the company reports its progress in autoimmune CAR T-cell therapy and related corporate developments.
Kyverna Therapeutics (Nasdaq: KYTX) appointed Nadia Dac as Chief Commercial Officer effective May 4, 2026. Ms. Dac has more than 30 years of commercial leadership and will lead strategy and execution for miv-cel (KYV-101), positioned for a potential first approval in stiff person syndrome. Kyverna granted a 300,000-share option as an inducement, vesting over four years, with exercise price set at the closing stock price on the grant date.
Kyverna (NASDAQ: KYTX) reported positive registrational KYSA-8 results for miv-cel in stiff person syndrome (SPS), with a single dose showing statistically significant, durable benefit and a manageable safety profile.
Key results: T25FW improved median 46% (Week 16, p=0.0003); 81% had ≥20% improvement; all 26 patients discontinued chronic immunotherapies through last follow-up; no high-grade CRS or ICANS observed.
Kyverna Therapeutics (NASDAQ: KYTX) reported longer-term Phase 2 KYSA-6 data for miv-cel in generalized myasthenia gravis showing deep, durable responses after a single 1×10^8 dose.
All seven patients achieved clinically meaningful MG-ADL and QMG improvements at 24 weeks; mean reductions were -8.5 MG-ADL and -11.3 QMG. Responses were sustained to 52 weeks in three patients. No high-grade CRS or ICANS observed; two transient grade 3/4 neutropenias resolved. The trial is enrolled into an FDA-aligned Phase 2/3 registrational design.
Kyverna Therapeutics (Nasdaq: KYTX) will host a conference call on April 22, 2026 at 7:00 a.m. ET to review primary analysis from the KYSA-8 registrational trial of miv-cel (KYV-101) in stiff person syndrome and longer-term follow-up from KYSA-6 in generalized myasthenia gravis.
Data are being presented orally and as posters at the American Academy of Neurology Annual Meeting, April 18-22, 2026 in Chicago. The call requires registration and will be available via live webcast and archived replay on Kyverna's Investor Relations site.
Kyverna Therapeutics (NASDAQ: KYTX) reported fourth-quarter and full-year 2025 results and a business update focused on its autoimmune CAR T candidate miv-cel (KYV-101). The company expects a BLA submission in 1H 2026, plans a commercial launch by year-end 2026, and reports $279.3 million cash runway into 2028 to fund launch and Phase 3 gMG.
Key clinical highlights include statistically significant SPS registrational topline results, positive interim KYSA-6 gMG data with Phase 3 enrollment started, and encouraging investigator-led PMS and RA results. Full-year net loss was $161.3 million.
Kyverna Therapeutics (NASDAQ: KYTX) will present new neuroimmunology data at the American Academy of Neurology (AAN) Annual Meeting, April 18-22, 2026 in Chicago.
Oral sessions include primary analysis from the registrational KYSA-8 trial in stiff person syndrome showing statistically significant clinical benefit and updated KYSA-6 Phase 2 results in generalized myasthenia gravis. Multiple posters cover real-world outcomes and Phase 3 design.
Kyverna Therapeutics (Nasdaq: KYTX) announced management will attend investor conferences in March 2026, including a Leerink fireside chat and Jefferies investor meetings.
The Leerink fireside chat is scheduled for March 9, 2026 at 11:20 a.m. ET; a live webcast and a 90-day replay will be available via the company investor website, according to the company.
Kyverna Therapeutics (Nasdaq: KYTX) announced the appointments of Sravan K. Emany and Andrew Miller, Ph.D. to its Board of Directors effective Feb. 24, 2026. Emany will serve as Audit Committee Chair following Dan Spiegelman’s departure from the board. The hires add finance, capital-markets, clinical development and product-approval experience as Kyverna advances autoimmune CAR T programs toward commercialization.
The company highlighted Emany’s CFO and investment-banking background and Miller’s R&D leadership and role in Karuna’s acquisition and KarXT development.
Kyverna Therapeutics (NASDAQ: KYTX) named Mayo Pujols as Chief Technology Officer, effective February 9, 2026, succeeding Karen Walker who will consult during the transition.
Pujols brings 30+ years in cell and gene therapy manufacturing. Kyverna disclosed an inducement option for 300,000 shares vesting over four years; grant tied to the closing stock price on the grant date.
Kyverna Therapeutics (NASDAQ: KYTX) provided a corporate update and 2026 priorities on Jan 12, 2026, highlighting late‑stage progress for its CAR T candidate miv‑cel. Key items: Kyverna plans to file a BLA for stiff person syndrome (SPS) in 1H 2026 after positive registrational topline data; the first patient has enrolled in the Phase 3 portion of the gMG KYSA‑6 trial; an IND for KYV‑102 was accepted by FDA in Jan 2026; a December 2025 follow‑on offering raised approximately $105M, and cash, cash equivalents, and marketable securities were ~$279M as of Dec 31, 2025, extending runway into 2028. Christi Shaw was appointed Executive Chairperson to strengthen CAR T commercialization experience.